{"refrec":{"BRefID":301294,"RR":"Goldstein, L.J.; Gurtler, J.; Del Prete, S.A.; Tjulandin, S.; Semiglazov, V.F.; Bayever, E.; Michiels, B. (2014). Trabectedin as a single-agent treatment of advanced breast cancer after Anthracycline and Taxane treatment: a multicenter, randomized, phase II study comparing 2 administration regimens. Clinical Breast Cancer 14(6): 396-404. https://dx.doi.org/10.1016/j.clbc.2014.06.006","BEntID":293533,"PublicFlag":1,"CheckedFlag":1,"wosflag":1,"vabbflag":0,"RefStringPartII":". Clinical Breast Cancer 14(6): 396-404. https://dx.doi.org/10.1016/j.clbc.2014.06.006","DocTypID":8,"DocType":"Journal article","MarineFlag":0,"FreshFlag":0,"BrackishFlag":0,"TerrestrialFlag":0,"Authorstring":"Goldstein, L.J.; Gurtler, J.; Del Prete, S.A.; Tjulandin, S.; Semiglazov, V.F.; Bayever, E.; Michiels, B.","OrigTitleTranslFlag":0,"Authorstringtrunc":"Goldstein, L.J. et al.","Englishabstract":"

Background

The purpose of this study was to assess the efficacy and safety of trabectedin for advanced breast cancer.

Patients and Methods

In an open-label, phase II, multicenter study, women with advanced breast cancer previously treated with ≤ 2 lines of chemotherapy for advanced disease, including both anthracyclines and taxanes, were randomized (1:1) to 3-hour infusions of trabectedin 1.3 mg/m2 once every 3 weeks (1/3 treatment arm) or 0.58 mg/m2 every week for 3 of 4 weeks (3/4 treatment arm). The primary end point was objective response. Secondary end points included time to progression (TTP), progression-free survival (PFS), and overall survival (OS).

Results

Fifty-two women (median age, 50 years; median chemotherapy agents, 4) were enrolled. Relative trabectedin dose intensities were 81% and 76% in the 1/3 and 3/4 treatment arms, respectively. Objective response rates were 12% (3 of 25) and 4% (1 of 27), respectively. Stable disease was observed in 14 (56%) and 11 (41%) patients in the 1/3 and 3/4 treatment arms, respectively, with median durations of 3.5 and 3.7 months. Median TTP and PFS were higher in the 1/3 treatment arm (3.1 months each) than in the 3/4 treatment arm (2.0 months each). At a median follow-up of 7 months in both treatment arms, median OS was not reached in the 1/3 treatment arm and was 9.4 months in the 3/4 treatment arm. The most frequent drug-related adverse events in the 1/3 and 3/4 treatment arms, respectively, were alanine aminotransferase (ALT) level increases (68% vs. 63%), nausea (56% vs. 59%), and asthenia (56% vs. 48%). Neutropenia and increases in ALT levels were the most frequent grade 3/4 events. Both types of events were usually transient and reversible.

Conclusion

In the population studied, trabectedin showed a manageable safety profile for both regimens analyzed. There were higher objective response rates and a longer PFS in the 1/3 treatment arm compared with the 3/4 treatment arm.

","AbstractOtherLang":null,"BibLvlCode":"AS","StandardTitle":"Trabectedin as a single-agent treatment of advanced breast cancer after Anthracycline and Taxane treatment: a multicenter, randomized, phase II study comparing 2 administration regimens","OrigTitleLangCode":"en","OrigTitleLangCodeExtended":"eng","OrigTitleLangID":15,"DateLastModified":{"date":"2024-12-10 01:33:17.368041","timezone_type":1,"timezone":"+01:00"},"UserAccessRight":null,"UserAccID":null,"AuthorKeywords":"Ecteinascidin-743; Objective response rate; Overall survival;Progression-free survival; Safety; Time to progression","OtherDescriptors":null,"Notes":null,"AnaPub":2014,"MonPub":null,"DateUpdate":"2022-05-18","DateCreate":"2018-09-14","SecASFANote":null,"ConfID":null,"PeerRev":1,"VlizCoreFlag":1,"WoScode":"WOS:000345883000004","VABBcode":null,"OpenAcc":0,"DOI":"10.1016/j.clbc.2014.06.006"},"refs":null,"anarec":{"AnaID":301294,"PubliDate":2014,"Pagination":"396-404","XtraPublOfAnaID":null,"ISBN":null,"Volume":"14","Issue":"6","BRefMon":null,"BRefMonRR":null,"BRefXtra":null,"BRefXtraRR":null,"SerBRefID":265899,"SerRR":"Clinical Breast Cancer: Dallas. ISSN 1526-8209; e-ISSN 1938-0666","StandardTitleSer":"Clinical Breast Cancer","ISSN":"1526-8209","AbbrevSer":null,"StandardTitleMon":null,"StartPage":396,"Pages":9,"ToPubliDate":null,"BRefBibLvlCode":"S","SerNotes":null},"monrec":null,"serrec":null,"relations":null,"relationsRev":null,"addrec":null,"othpubs":null,"ownerships":null,"authors":[{"AutName":"Goldstein","Firstname":"Lori","Initials":"L.J.","Affiliation":null,"Discriminator":null,"CorporateFlag":0,"BEntID":293533,"AutID":344304,"OrderNr":1,"DegrID":null,"EditorFlag":0,"CorrespFlag":0,"IllustratorFlag":0,"ReviserFlag":0,"TranslatorFlag":0,"InsAcronym":null,"InsFSN":null,"ORCID":null,"PersID":null,"InsID":null},{"AutName":"Gurtler","Firstname":"Jayne","Initials":"J.","Affiliation":null,"Discriminator":null,"CorporateFlag":0,"BEntID":293533,"AutID":344305,"OrderNr":2,"DegrID":null,"EditorFlag":0,"CorrespFlag":0,"IllustratorFlag":0,"ReviserFlag":0,"TranslatorFlag":0,"InsAcronym":null,"InsFSN":null,"ORCID":null,"PersID":null,"InsID":null},{"AutName":"Del Prete","Firstname":"Salvatore","Initials":"S.A.","Affiliation":null,"Discriminator":null,"CorporateFlag":0,"BEntID":293533,"AutID":344306,"OrderNr":3,"DegrID":null,"EditorFlag":0,"CorrespFlag":0,"IllustratorFlag":0,"ReviserFlag":0,"TranslatorFlag":0,"InsAcronym":null,"InsFSN":null,"ORCID":null,"PersID":null,"InsID":null},{"AutName":"Tjulandin","Firstname":"Sergei","Initials":"S.","Affiliation":null,"Discriminator":null,"CorporateFlag":0,"BEntID":293533,"AutID":344307,"OrderNr":4,"DegrID":null,"EditorFlag":0,"CorrespFlag":0,"IllustratorFlag":0,"ReviserFlag":0,"TranslatorFlag":0,"InsAcronym":null,"InsFSN":null,"ORCID":null,"PersID":null,"InsID":null},{"AutName":"Semiglazov","Firstname":"Vladimir","Initials":"V.F.","Affiliation":null,"Discriminator":null,"CorporateFlag":0,"BEntID":293533,"AutID":344308,"OrderNr":5,"DegrID":null,"EditorFlag":0,"CorrespFlag":0,"IllustratorFlag":0,"ReviserFlag":0,"TranslatorFlag":0,"InsAcronym":null,"InsFSN":null,"ORCID":null,"PersID":null,"InsID":null},{"AutName":"Bayever","Firstname":"Eliel","Initials":"E.","Affiliation":null,"Discriminator":null,"CorporateFlag":0,"BEntID":293533,"AutID":344309,"OrderNr":6,"DegrID":null,"EditorFlag":0,"CorrespFlag":0,"IllustratorFlag":0,"ReviserFlag":0,"TranslatorFlag":0,"InsAcronym":null,"InsFSN":null,"ORCID":null,"PersID":null,"InsID":null},{"AutName":"Michiels","Firstname":"Bart","Initials":"B.","Affiliation":"Janssen Research & Development","Discriminator":null,"CorporateFlag":0,"BEntID":293533,"AutID":344310,"OrderNr":7,"DegrID":null,"EditorFlag":0,"CorrespFlag":0,"IllustratorFlag":0,"ReviserFlag":0,"TranslatorFlag":0,"InsAcronym":null,"InsFSN":null,"ORCID":null,"PersID":null,"InsID":null}],"mapdetails":null,"datasets":null,"monographs":null,"monparts":null,"serparts":null,"BEntOpen":null,"BEntPrivate":null,"availability":[{"BInstID":377210,"LibID":36,"BRefID":301294,"EmbargoDate":null,"FullEmbargoDate":null,"PhysMedID":16,"hasOCRd":null,"ShelfLocCode":"377210","RFID":null,"PaidValue":null,"Medium":"Server","Description":"Interne VLIZ documenten","Acronym":"VLIZ","Library":"Vlaams Instituut voor de Zee","DutchTerm":"Non-open access","URL":null,"ClassifID":228,"Classification":"Non-open access","ReqLink":1,"ClassifTypID":3,"URLLocation":"https://www.vliz.be/imisdocs/publications/","SubDir":1,"InternalReq":1,"LoggedInReq":1,"Disclaimer":"Disclaimer_VLIZ_Intern","DutchDisclaimer":"

Deze publicatie is enkel beschikbaar voor persoonlijk gebruik binnen de Innovocean site
en mag op geen enkele manier verder worden verspreid.

","FileFormat":".pdf","FileDescr":"pdf","InsPub":1,"InsID":36,"FileFormID":6,"LendableFlag":1,"PublicFlag":1,"orderLib":"A","Notes":null,"AccConID":null,"AccessConstraint":null,"LicURL":null}],"litstyles":null,"thespers":null,"arch2discl":null,"SERpubls":null,"MONpubls":null,"pictures":[],"thestermsPath":null,"thestermsASFA":null,"taxtermsASFA":null,"geotermsASFA":null,"collections":null,"conf":null,"proj":null,"Physdatasets":null,"spcols":{"222":{"SpName":"BMB - Belgische Mariene Bibliografie","SpColID":222,"ParSpColID":null,"TopParID":null,"ShortName":"BMB","URLLocation":null,"LibID":36,"OpenRepoFlag":null,"SpTypID":null,"TopParIDNotWebsite":null,"SpColPath":"BMB"}},"doi":null,"publs":null,"serparttypes":null,"monauthors":null,"MParts":null,"SParts":null,"hLibs":null,"langs":[{"BEntID":293533,"AbstractFlag":0,"LangID":15,"LangCode":"en","Lang":"English","DutchTerm":"Engels","LangCodeExtended":"eng"},{"BEntID":293533,"AbstractFlag":1,"LangID":15,"LangCode":"en","Lang":"English","DutchTerm":"Engels","LangCodeExtended":"eng"}],"urls":[{"URL":"https://dx.doi.org/10.1016/j.clbc.2014.06.006","externalID":"10.1016/j.clbc.2014.06.006","URLTypeCode":"DOI","URLID":67836,"URLTypID":13,"URLType":"DOI","URLPrefix":"http://dx.doi.org/"}],"thesterms":null,"taxterms":null,"geoterms":null,"othterms":null,"asfacodes":null,"asfa2codes":null,"thestermsFRIS":null,"taxtermsFRIS":null,"geotermsFRIS":null,"othtermsFRIS":null,"resmessage":"","complete":1,"sessions":{"newSesName":"Lyssens, Liesbeth, L.","newSesDate":{"date":"2018-09-14 10:19:03.203000","timezone_type":3,"timezone":"Europe/Brussels"},"updSesName":"Chisala, Chilekwa, C.","updSesDate":{"date":"2022-05-18 08:18:41.620000","timezone_type":3,"timezone":"Europe/Brussels"}}}